US equities |
SPCX $144.75 ▼-9.14% MU $856.49 ▼-6.26% NVDA $212.21 ▼-4.40% META $648.85 ▼-6.98% TSLA $374.58 ▼-3.08% AAPL $348.22 ▲+1.23% AMD $507.93 ▼-8.10% SNDK $1,260.93 ▼-8.51%
FinancialContent

Articles published by Royalty Pharma plc

< Previous 1 2 3 4 Next >
News headline image
Royalty Pharma declares fourth quarter 2026 dividend
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma to present at upcoming investor conferences
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma reports second quarter 2026 results
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma declares third quarter 2026 dividend
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma to present at upcoming investor conferences
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma reports first quarter 2026 results
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma Declares Second Quarter 2026 Dividend
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma Announces Expansion of Leadership Team
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX ZYME
News headline image
Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma Reports Q4 and Full Year 2025 Results
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX TEVA
News headline image
Royalty Pharma Announces Dividend Increase
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
News headline image
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
< Previous 1 2 3 4 Next >